ARV`s

Aspen – a global leader in generic ARVs
Aspen remains committed to fighting HIV/AIDS by manufacturing quality generic ARVs which comply with all the physical, chemical and bio-equivalence specifications expected of good medicine.

Aspen made international headlines inNike August 2003 when it launched Aspen-Stavudine – the first generic ARV drug developed and manufactured in Africa. The ARV portfolio has received significant attention with Aspen’s ongoing commitment to assisting in finding a meaningful solution in the fight against HIV/Aids. Aspen’s basket is presently comprised of more than ten ARVs with additional products being launched periodically in line with regulatory approvals being secured.

Today Aspen is proudly regarded as one of the leading global players in generic ARVs. The Group’s credibility has been earned through its numerous world first achievements in the field of ARVs namely:     

• Aspen was the world’s first pharmaceutical company to pioneer the manufacture and development of generic ARVs in Africa.

• Aspen was the world’s first generics producer to receive FDA approval for the manufacture of selected generic ARVs containing Lamivudine/Zidovudine and Nevirapine for the treatment of HIV/Aids at its Oral Solid Dose Facility in Port Elizabeth, South Africa.

• Aspen was the world’s first pharmaceutical manufacturer to be granted voluntary generic ARV licenses from leading multinationals

• The Clinton Foundation chose Aspen as the first southern hemisphere company to manufacture generic ARVs for their program.

• The South African Government awarded Aspen the lion’s share of its first ARV tender equating to 58% by volume. Aspen secured more than 70% by volume of the second ARV tender awarded by the South African Government

• At June 2008, Aspen held more than 30% of the share in the South African ARV private market

• The South African Government’s ARV treatment programme is the larges of its kind in the world. To date, Aspen has played a leading role in confronting the severity of the HIV/Aids pandemic. Aspen is the leading provider of ARVs to the private and public sectors and supports key HIV funders’ programmes in supplying low-cost, high quality ARV medicines to Africa

• Aspen presently provides ARVs to an estimated 600 000 HIV/Aids patients across the African continent

Aspen – a global leader in generic ARVs

Aspen remains committed to fighting HIV/AIDS by manufacturing quality generic ARVs which comply with all the physical, chemical and bio-equivalence specifications expected of good medicine.

Aspen made international headlines in August 2003 when it launched Aspen-Stavudine – the first generic ARV drug developed and manufactured in Africa. The ARV portfolio has received significant attention with Aspen’s ongoing commitment to assisting in finding a meaningful solution in the fight against HIV/Aids. Aspen’s basket is presently comprised of more than ten ARVs with additional products being launched periodically in line with regulatory approvals being secured.

Today Aspen is regarded as one of the leading global players in generic ARVs. The Group’s credibility has been earned through its numerous world first achievements in the field of ARVs namely:

• Aspen was the world’s first pharmaceutical company to pioneer the manufacture and development of generic ARVs in Africa.

• Aspen was the world’s first generics producer to receive FDA approval for the manufacture of selected generic ARVs containing Lamivudine/Zidovudine and Nevirapine for the treatment of HIV/Aids at its Oral Solid Dose Facility in Port Elizabeth, South Africa.

• Aspen was the world’s first pharmaceutical manufacturer to be granted voluntary generic ARV licenses from leading multinationals.

• The Clinton Foundation chose Aspen as the first southern hemisphere company to manufacture generic ARVs for their program.

• The South African Government awarded Aspen the lion’s share of its first ARV tender equating to 58% by volume. Aspen secured more than 70% by volume of the second ARV tender awarded by the South African Government.

• The South African Government’s ARV treatment programme is the largest of its kind in the world. In the tender for the supply of ARVs under this programme, adjudicated in 2011, Aspen was awarded 41% of the value of the ARVs to be supplied over a two-year period.

• To date, Aspen has played a leading role in confronting the severity of the HIV/Aids pandemic. Aspen is the leading provider of ARVs to the private and public sectors and supports key HIV funders’ programmes in supplying low-cost, high quality ARV medicines to Africa

• Aspen's ARVs presently support close to 900 000 patients in South Africa.